OIS at AAO 2015

Ocata Therapeutics

Nov 12, 2015 11:49am ‐ Nov 12, 2015 11:57am


Ocata Therapeutics is clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technologies. The company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration.


  • Eddy Anglade, MD, Chief Medical Officer, Ocata Therapeutics

You must be logged in and own this session in order to post comments.